Exhibit 99.1 Sarepta Therapeutics Announces Third Quarter 2025 Financial Results and Recent Corporate Developments, Including Completion of Its Confirmatory Study, ESSENCE Based on the encouraging trends seen in ESSENCE, the substantial real-world evidence, and the positive safety profile of AMONDYS 45 and VYONDYS 53, Sarepta intends to schedule a meeting with the U.S. Food and Drug Administration (FDA) to discuss the possibility of converting from accelerated to traditional approval. Sarepta continues to a ...

Core Insights - The Massachusetts biotech industry is experiencing a significant downturn in pipeline growth, venture funding, federal support, and sector employment, indicating a troubling trend for the U.S. biotech landscape [2][3][4] Industry Overview - Massachusetts, a leading hub for biotech R&D, is facing a painful decline in investor confidence, which could jeopardize the U.S.'s global leadership in the biotech sector [4] - The report from MassBio highlights that from last year through the first half of 2025, the biotech industry has seen limited growth in overall funding deals, leading to layoffs and reduced innovation [3][5] Employment Trends - The biotech sector in Massachusetts has seen over 1,800 job losses in the third quarter of this year, totaling 4,100 job losses in 2025 so far [5] - Major companies like Moderna and Sarepta Therapeutics have reduced their workforces by 10% and 36%, respectively, contributing to the decline in the biotech workforce [5] Funding Landscape - Despite venture capital funding deals in the first half of 2025 nearly matching the previous year, total funding was down by 17%, indicating a lack of financial support for smaller biotech companies [6][7] - The top 10 funding deals accounted for more than half of the total funding, leaving smaller players struggling for financial resources [7]

Core Insights - Sarepta Therapeutics, Inc. (NASDAQ: SRPT) has faced scrutiny due to disappointing results from recent clinical trials, impacting its stock price significantly [1] - The company operates in the biotechnology sector, focusing on innovative drug development through unique mechanisms of action and first-in-class therapies [1] Company Overview - Sarepta Therapeutics is involved in developing therapies that aim to reshape treatment paradigms in the biotech industry [1] - The company has a pipeline that includes both early clinical candidates and commercial-stage products, indicating a diverse range of development stages [1] Market Analysis - The biotechnology sector is characterized by the potential for breakthrough science to yield substantial returns, but it also requires careful scrutiny of clinical trial designs and competitive landscapes [1] - The analysis emphasizes the importance of evaluating the science behind drug candidates and understanding the market opportunities available [1]

Core Insights - Sarepta Therapeutics, Inc. (NASDAQ: SRPT) has faced scrutiny due to disappointing results from recent clinical trials, impacting its stock price significantly [1] Company Overview - Sarepta Therapeutics is focused on biotechnology, particularly in developing innovative therapies with unique mechanisms of action and first-in-class treatments [1] - The company aims to reshape treatment paradigms through its platform technologies [1] Investment Analysis - The analysis emphasizes the importance of evaluating the scientific basis of drug candidates, the competitive landscape, clinical trial design, and potential market opportunities [1] - The biotech sector is characterized by the potential for breakthrough science to yield substantial returns, necessitating careful scrutiny of investments [1]

Core Insights - Sarepta Therapeutics Inc. (NASDAQ:SRPT) stock is experiencing an upward trend without any specific news to explain the increase [1] - The company is set to present data on its gene therapy, delandistrogene moxeparvovec, for Duchenne muscular dystrophy (DMD) this week [1] Group 1: Clinical Developments - Sarepta will present results from multiple studies related to the delandistrogene moxeparvovec clinical development program, including a real-world evidence study on pulmonary function in advanced-stage DMD patients treated with casimersen [2] - Independent studies on delandistrogene moxeparvovec will also be presented, including an abstract on the use of sirolimus prophylaxis to mitigate potential acute liver injury in patients receiving the therapy [3] - Results from the EMERGENE phase 3 study on SGCB expression and safety following bidridistrogene xeboparvovec treatment in LGMD2E/R4 patients will be shared [4] Group 2: Regulatory Updates - The FDA had previously requested Sarepta to halt shipments of its drug after a reported death in a young patient in Brazil, but reversed its decision allowing the company to resume shipments for certain patients [4][5] Group 3: Stock Performance - As of the latest update, Sarepta Therapeutics stock is trading at $23.12, with a premarket increase of 4.67% to $24.20 [7][8]

Group 1 - Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has seen a significant stock price increase, rising 15.68% to close at $22.35, marking its fifth consecutive day of gains as investors prepare for preliminary results from a clinical trial for a drug targeting myotonic dystrophy type 1 (DM1) [1] - The company plans to announce preliminary results for the first phase of its clinical trial for SRP-1003 in DM1 patients in the second half of the year, alongside other clinical trials for various diseases [2] - Arrowhead Pharmaceuticals, the original developer of SRP-1003, has acquired a $174 million stake in Sarepta through a privately negotiated block sale, indicating strong support for the company's potential [3] Group 2 - Sarepta Therapeutics has entered into an agreement with Arrowhead Pharmaceuticals to transfer 2.66 million shares to settle a $50 million obligation, part of a larger $100 million milestone payment [4]

Group 1 - The article highlights the challenges faced by Sarepta Therapeutics, Inc. in 2025, indicating it has been a particularly difficult year for the company [1] - The investing group Haggerston BioHealth offers insights for both novice and experienced biotech investors, including catalysts to watch and buy/sell ratings [2] - The group provides detailed financial analyses, including product sales forecasts and integrated financial statements for major pharmaceutical companies [2]

Core Insights - Sarepta Therapeutics, Inc. is recognized as a leader in precision genetic medicine for rare diseases [1] - The company will present at the 30th Annual Congress of the World Muscle Society (WMS) 2025 Congress scheduled for October 7-11, 2025, in Vienna, Austria [1] - Presentations will include results from multiple studies related to the delandistrogene moxeparvovec clinical development program, as well as a real-world evidence study focusing on pulmonary function in advanced-stage patients [1]

Core Viewpoint - Kuehn Law, PLLC is investigating potential breaches of fiduciary duties by certain officers and directors of Sarepta Therapeutics, Inc. related to the misrepresentation of safety risks associated with the ELEVIDYS treatment [1] Group 1: Allegations Against Sarepta Therapeutics - Insiders at Sarepta Therapeutics allegedly caused the company to misrepresent or fail to disclose significant safety risks posed by the ELEVIDYS treatment [1] - The trial regimes and protocols for ELEVIDYS reportedly failed to detect severe side effects, leading to concerns about patient safety [1] - The severity of adverse events from ELEVIDYS treatment may result in the company halting recruitment and dosing in trials, attracting regulatory scrutiny, and increasing risks around the therapy's approvals [1] - Insiders are accused of materially misleading stakeholders and lacking a reasonable basis for their positive statements regarding ELEVIDYS [1]

Analyst Upgrades and Downgrades - Barclays analyst Eddie Kim upgraded Helmerich & Payne, Inc. from Equal-Weight to Overweight, raising the price target from $17 to $25, with shares closing at $20.54 [3] - UBS analyst Alex Kramm upgraded FactSet Research Systems Inc. from Neutral to Buy but lowered the price target from $480 to $425, with shares closing at $289.15 [3] - BMO Capital analyst Kostas Biliouris upgraded Sarepta Therapeutics, Inc. from Market Perform to Outperform, maintaining the price target at $50, with shares closing at $17.43 [3] - Evercore ISI Group analyst Daniel Markowitz upgraded Repligen Corporation from In-Line to Outperform, raising the price target from $130 to $155, with shares closing at $122.30 [3] - Wells Fargo analyst Zachary Fadem upgraded Brinker International, Inc. from Equal-Weight to Overweight, boosting the price target from $165 to $175, with shares closing at $136.35 [3]